PharVision Advisers’s Adient ADNT Stock Holding History

PharVision Advisers’s Portfolio ADNT Stock Details ADNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,556	Closed	-$351K	–	675
2025 Q3	$351K	Buy	+14,556	New	+$340K	0.2%	140

Other funds holding ADNT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

HHAM

HITE Hedge Asset Management Braintree, Massachusetts $1.77B AUM 38.67% 1-Year Est. Return

PharVision Advisers's ADNT Position: Q4 2025 in Review

PharVision Advisers sold out of Adient (ADNT) in Q4 2025, closing a stake of 14,556 shares — an estimated $351K sold.

PharVision Advisers first reported a position in ADNT in Q3 2025 and held it in 1 quarter. The position peaked at $351K in Q3 2025. 288 funds tracked by Wall St. Rank hold ADNT as of Q4 2025.

PharVision Advisers reported no remaining Adient position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 14,556 Adient shares in Q4 2025, an estimated $351K.
PharVision Advisers first reported a position in Adient in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Adient position peaked at $351K in Q3 2025.
288 funds tracked by Wall St. Rank held Adient as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.